Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma

Background Aldo‐keto reductase family 1 member B10 (AKR1B10) expression in oral squamous cell carcinoma (OSCC) tissue specimens is correlated with the progression and prognosis of OSCC. Methods Saliva samples were obtained from 35 normal controls and 86 patients with OSCC before cancer surgery. The...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2018-12, Vol.40 (12), p.2642-2647
Main Authors: Ko, Hui‐Hsin, Peng, Hsin‐Hui, Cheng, Shih‐Jung, Kuo, Mark Yen‐Ping
Format: Article
Language:English
Subjects:
Adult
AKR1B10
Aldo-Keto Reductases - analysis
areca quid
Biomarkers, Tumor - analysis
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Chewing
Disease Progression
Early Detection of Cancer - methods
Enzyme-linked immunosorbent assay
Female
Head and neck
Humans
Kaplan-Meier Estimate
Male
Medical prognosis
Middle Aged
Mouth Neoplasms - mortality
Mouth Neoplasms - pathology
Oral cancer
Oral squamous cell carcinoma
Prognosis
Reductase
Saliva
Saliva - chemistry
Squamous cell carcinoma
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Aldo‐keto reductase family 1 member B10 (AKR1B10) expression in oral squamous cell carcinoma (OSCC) tissue specimens is correlated with the progression and prognosis of OSCC. Methods Saliva samples were obtained from 35 normal controls and 86 patients with OSCC before cancer surgery. The AKR1B10 levels were determined using enzyme‐linked immunosorbent assay (ELISA). Results The mean salivary AKR1B10 levels were significantly higher in the patients with OSCC than in the normal controls (P < .001). Higher salivary AKR1B10 levels were significantly associated with larger tumor size, more advanced clinical stage, and areca quid chewing habit. Patients with OSCC with a higher salivary AKR1B10 level (>646 pg/mL) had a significantly poorer survival than those with a lower (≤646 pg/mL) salivary AKR1B10 level (P = .026). Conclusion The salivary AKR1B10 level may be a promising biomarker for screening high‐risk patients with OSCC and monitoring the progression of OSCC.
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.25370